HanAll Biopharma Reports Q2 Sales of 44.3 Billion Won... "Balanced Growth of Key Products"
9% Increase Year-on-Year
Net Loss Due to One-Time Expenses
Topline Results to Be Announced in the Second Half
On July 29, HanAll Biopharma announced that its consolidated sales for the second quarter reached 44.3 billion won, with operating profit at 5.6 billion won. These figures represent increases of 9% and 389%, respectively, compared to the same period last year.
The pharmaceutical business in the second quarter maintained strong results, driven by the balanced growth of its major products. The probiotic drug "Biotop" and the non-absorbable antibiotic "Normix" both exceeded cumulative sales of 14.8 billion won and 10 billion won, respectively, during the first half of the year. The prostate cancer and central precocious puberty treatment "Eligard" also continued to see stable growth in prescriptions.
Operating profit came in at 5.6 billion won, as previously deferred revenue was recognized after the completion of the global Phase 3 trial for Batoclimab in thyroid eye disease (TED). On the other hand, net loss amounted to 19.2 billion won, due to a one-time increase in expenses such as impairment losses related to development projects.
In the research and development (R&D) segment, the company’s next-generation autoimmune disease treatment, IMERO-PLUVAT, demonstrated efficacy in actual patients for the first time through interim results from its registration clinical trial in difficult-to-treat rheumatoid arthritis (D2T RA).
In the second half of the year, topline results are scheduled to be announced for the registration clinical study of IMERO-PLUVAT in difficult-to-treat rheumatoid arthritis and for the Phase 2 clinical trial in cutaneous lupus erythematosus (CLE).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A HanAll Biopharma official stated, "We are maintaining a solid business foundation based on stable growth of our key pharmaceuticals and research and development achievements," and added, "Through the clinical results scheduled in the second half, we expect to validate the value of IMERO-PLUVAT in earnest."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.